Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Insmed Inc INSM

Healthcare Biotechnology
Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs... see more

Recent & Breaking News (NDAQ:INSM)

Rodman & Renshaw 2014 Annual Global Investment Conference to be held in New York from September 8 to 10, 2014

Business Wire August 11, 2014

Insmed Reports Second Quarter 2014 Financial Results

Business Wire August 6, 2014

Insmed Provides Regulatory Update for ARIKAYCE

Business Wire August 4, 2014

Insmed to Present at the JMP Securities Healthcare Conference

eTeligis June 20, 2014

Insmed Appoints David R. Brennan to Its Board of Directors

eTeligis May 29, 2014

Insmed Announces Positive Open Label Data from Phase 2 Clinical Trial of ARIKAYCE for Treatment Resistant Nontuberculous Mycobacterial Lung Infections

Business Wire May 20, 2014

Insmed Announces Data Presentations for ARIKAYCE in Two Orphan Lung Diseases at the American Thoracic Society Meeting

eTeligis May 13, 2014

Insmed to Participate in the Bank of America Merrill Lynch 2014 Health Care Conference

eTeligis May 12, 2014

Insmed Reports First Quarter 2014 Financial Results

eTeligis May 8, 2014

Insmed to Participate in the 13th Annual Needham & Co. Healthcare Conference

Marketwired April 7, 2014

Insmed to Participate in the 13th Annual Needham & Co. Healthcare Conference

eTeligis April 7, 2014

Insmed Announces Leadership Team Transitions and Appointments to Expand Support for Growth Opportunities

Marketwired April 2, 2014

Insmed Announces Leadership Team Transitions and Appointments to Expand Support for Growth Opportunities

Marketwired April 2, 2014

Insmed Announces Results from Phase 2 Clinical Trial for Treatment Resistant Nontuberculous Mycobacterial Lung Infections

Business Wire March 26, 2014

Insmed to Announce Results From U.S. Phase 2 Clinical Trial for Treatment Resistant Nontuberculous Mycobacteria Lung Infections

Marketwired March 25, 2014

Insmed to Announce Results From U.S. Phase 2 Clinical Trial for Treatment Resistant Nontuberculous Mycobacteria Lung Infections

Marketwired March 25, 2014

Insmed to Announce Results From U.S. Phase 2 Clinical Trial for Treatment Resistant Nontuberculous Mycobacteria Lung Infections

eTeligis March 25, 2014

Insmed Reports 2013 Fourth Quarter and Full Year Financial Results

eTeligis March 6, 2014

Insmed Provides Interim Update from Two-Year, Open-Label Extension Study of ARIKACE to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients

Business Wire February 19, 2014

RDInvesting Provides Investors with Free In-Depth Equity Reports on INSM, KBH, MDRX and SWKS

Accesswire February 12, 2014
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse
Later
Participate
Not interested